-
Je něco špatně v tomto záznamu ?
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
J. Rech, K. Tascilar, M. Hagen, A. Kleyer, B. Manger, V. Schoenau, AJ. Hueber, S. Kleinert, X. Baraliakos, J. Braun, U. Kiltz, M. Fleck, A. Rubbert-Roth, DM. Kofler, F. Behrens, M. Feuchtenberger, M. Zaenker, R. Voll, N. Venhoff, J. Thiel, C....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu randomizované kontrolované studie, multicentrická studie, časopisecké články
NLK
ProQuest Central
od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
- MeSH
- abatacept škodlivé účinky MeSH
- antirevmatika * škodlivé účinky MeSH
- artralgie chemicky indukované MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- revmatoidní artritida * diagnostické zobrazování farmakoterapie MeSH
- výsledek terapie MeSH
- zánět farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain to be developed. We aimed to assess whether 6-month treatment with abatacept improves inflammation in preclinical rheumatoid arthritis. METHODS: The abatacept reversing subclinical inflammation as measured by MRI in ACPA positive arthralgia (ARIAA) study is a randomised, international, multicentre, double-blind, placebo-controlled trial done in 14 hospitals and community centres across Europe (11 in Germany, two in Spain, and one in the Czech Republic). Adults (aged ≥18 years) with ACPA positivity, joint pain (but no swelling), and signs of osteitis, synovitis, or tenosynovitis in hand MRI were randomly assigned (1:1) to weekly subcutaneous abatacept 125 mg or placebo for 6 months followed by a double-blind, drug-free, observation phase for 12 months. The primary outcome was the proportion of participants with any reduction in inflammatory MRI lesions at 6 months. The primary efficacy analysis was done in the modified intention-to-treat population, which included participants who were randomly assigned and received study medication. Safety analyses were conducted in participants who received the study medication and had at least one post-baseline observation. The study was registered with the EUDRA-CT (2014-000555-93). FINDINGS: Between Nov 6, 2014, and June 15, 2021, 139 participants were screened. Of 100 participants, 50 were randomly assigned to abatacept 125 mg and 50 to placebo. Two participants (one from each group) were excluded due to administration failure or refusing treatment; thus, 98 were included in the modified intention-to-treat population. 70 (71%) of 98 participants were female and 28 (29%) of 98 were male. At 6 months, 28 (57%) of 49 participants in the abatacept group and 15 (31%) of 49 participants in the placebo group showed improvement in MRI subclinical inflammation (absolute difference 26·5%, 95% CI 5·9-45·6; p=0·014). Four (8%) of 49 participants in the abatacept group and 17 (35%) of 49 participants in the placebo group developed rheumatoid arthritis (hazard ratio [HR] 0·14 [0·04-0·47]; p=0·0016). Improvement of MRI inflammation (25 [51%] of 49 participants in the abatacept group, 12 [24%] of 49 in the placebo group; p=0·012) and progression to rheumatoid arthritis (17 [35%] of 49, 28 [57%] of 49; HR 0·14 [0·04-0·47]; p=0·018) remained significantly different between the two groups after 18 months, 12 months after the end of the intervention. There were 12 serious adverse events in 11 participants (four [8%] of 48 in the abatacept group and 7 [14%] of 49 in the placebo group). No deaths occurred during the study. INTERPRETATION: 6-month treatment with abatacept decreases MRI inflammation, clinical symptoms, and risk of rheumatoid arthritis development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase. FUNDING: Innovative Medicine Initiative.
Department of Rheumatology and Clinical Immunology Charité Universitätsmedizin Berlin Berlin Germany
Department of Rheumatology Ruhr University Bochum Bochum Germany
Division of Internal Medicine Immanuel Klinikum Bernau Bernau Germany
Division of Rheumatology Asklepios Klinikum Bad Abbach Bad Abbach Germany
Division of Rheumatology Helios Clinic Vogelsang Gommern Vogelsang Germany
Division of Rheumatology Paracelsus Medical University Klinikum Nürnberg Nürnberg Germany
Division of Rheumatology Porz am Rhein Hospital Cologne Germany
Fraunhofer Institute for Translational Medicine and Pharmacology Frankfurt Germany
Rheumatology Clinic Kantonsspital St Gallen St Gallen Switzerland
Rheumatology Clinical Practice Erlangen Erlangen Germany
Rheumatology Med Bayern Ost Burghausen Germany
Rheumatology Practice Berlin Germany
Rheumazentrum Ruhrgebiet Herne Germany
Servicio de Reumatología Hospital Clínic de Barcelona Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006814
- 003
- CZ-PrNML
- 005
- 20240423155516.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(23)02650-8 $2 doi
- 035 __
- $a (PubMed)38364841
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rech, Juergen $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 245 10
- $a Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial / $c J. Rech, K. Tascilar, M. Hagen, A. Kleyer, B. Manger, V. Schoenau, AJ. Hueber, S. Kleinert, X. Baraliakos, J. Braun, U. Kiltz, M. Fleck, A. Rubbert-Roth, DM. Kofler, F. Behrens, M. Feuchtenberger, M. Zaenker, R. Voll, N. Venhoff, J. Thiel, C. Glaser, E. Feist, GR. Burmester, K. Karberg, J. Strunk, JD. Cañete, L. Senolt, M. Filkova, E. Naredo, R. Largo, G. Krönke, MA. D'Agostino, M. Østergaard, G. Schett
- 520 9_
- $a BACKGROUND: Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain to be developed. We aimed to assess whether 6-month treatment with abatacept improves inflammation in preclinical rheumatoid arthritis. METHODS: The abatacept reversing subclinical inflammation as measured by MRI in ACPA positive arthralgia (ARIAA) study is a randomised, international, multicentre, double-blind, placebo-controlled trial done in 14 hospitals and community centres across Europe (11 in Germany, two in Spain, and one in the Czech Republic). Adults (aged ≥18 years) with ACPA positivity, joint pain (but no swelling), and signs of osteitis, synovitis, or tenosynovitis in hand MRI were randomly assigned (1:1) to weekly subcutaneous abatacept 125 mg or placebo for 6 months followed by a double-blind, drug-free, observation phase for 12 months. The primary outcome was the proportion of participants with any reduction in inflammatory MRI lesions at 6 months. The primary efficacy analysis was done in the modified intention-to-treat population, which included participants who were randomly assigned and received study medication. Safety analyses were conducted in participants who received the study medication and had at least one post-baseline observation. The study was registered with the EUDRA-CT (2014-000555-93). FINDINGS: Between Nov 6, 2014, and June 15, 2021, 139 participants were screened. Of 100 participants, 50 were randomly assigned to abatacept 125 mg and 50 to placebo. Two participants (one from each group) were excluded due to administration failure or refusing treatment; thus, 98 were included in the modified intention-to-treat population. 70 (71%) of 98 participants were female and 28 (29%) of 98 were male. At 6 months, 28 (57%) of 49 participants in the abatacept group and 15 (31%) of 49 participants in the placebo group showed improvement in MRI subclinical inflammation (absolute difference 26·5%, 95% CI 5·9-45·6; p=0·014). Four (8%) of 49 participants in the abatacept group and 17 (35%) of 49 participants in the placebo group developed rheumatoid arthritis (hazard ratio [HR] 0·14 [0·04-0·47]; p=0·0016). Improvement of MRI inflammation (25 [51%] of 49 participants in the abatacept group, 12 [24%] of 49 in the placebo group; p=0·012) and progression to rheumatoid arthritis (17 [35%] of 49, 28 [57%] of 49; HR 0·14 [0·04-0·47]; p=0·018) remained significantly different between the two groups after 18 months, 12 months after the end of the intervention. There were 12 serious adverse events in 11 participants (four [8%] of 48 in the abatacept group and 7 [14%] of 49 in the placebo group). No deaths occurred during the study. INTERPRETATION: 6-month treatment with abatacept decreases MRI inflammation, clinical symptoms, and risk of rheumatoid arthritis development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase. FUNDING: Innovative Medicine Initiative.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a abatacept $x škodlivé účinky $7 D000069594
- 650 12
- $a antirevmatika $x škodlivé účinky $7 D018501
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a revmatoidní artritida $x diagnostické zobrazování $x farmakoterapie $7 D001172
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a artralgie $x chemicky indukované $7 D018771
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tascilar, Koray $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Hagen, Melanie $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Kleyer, Arnd $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Manger, Bernhard $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Schoenau, Verena $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Hueber, Axel J $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Division of Rheumatology, Paracelsus Medical University, Klinikum Nürnberg, Nürnberg, Germany
- 700 1_
- $a Kleinert, Stefan $u Rheumatology Clinical Practice Erlangen, Erlangen, Germany
- 700 1_
- $a Baraliakos, Xenofon $u Department of Rheumatology, Ruhr University Bochum, Bochum, Germany; Rheumazentrum Ruhrgebiet, Herne, Germany
- 700 1_
- $a Braun, Jürgen $u Department of Rheumatology, Ruhr University Bochum, Bochum, Germany; Rheumazentrum Ruhrgebiet, Herne, Germany
- 700 1_
- $a Kiltz, Uta $u Department of Rheumatology, Ruhr University Bochum, Bochum, Germany; Rheumazentrum Ruhrgebiet, Herne, Germany
- 700 1_
- $a Fleck, Martin $u Division of Rheumatology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany
- 700 1_
- $a Rubbert-Roth, Andrea $u Rheumatology Clinic, Kantonsspital St Gallen, St Gallen, Switzerland
- 700 1_
- $a Kofler, David M $u Division of Rheumatology and Clinical Immunology, Department 1 of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne and Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, Cologne, Germany
- 700 1_
- $a Behrens, Frank $u Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt, Germany
- 700 1_
- $a Feuchtenberger, Martin $u Rheumatology, Med Bayern Ost, Burghausen, Germany
- 700 1_
- $a Zaenker, Michael $u Division of Internal Medicine, Immanuel Klinikum Bernau, Bernau, Germany
- 700 1_
- $a Voll, Reinhard $u Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Venhoff, Nils $u Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Thiel, Jens $u Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Internal Medicine, Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Glaser, Cornelia $u Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Feist, Eugen $u Division of Rheumatology, Helios Clinic Vogelsang-Gommern, Vogelsang, Germany; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Burmester, Gerd R $u Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Karberg, Kirsten $u Rheumatology Practice, Berlin, Germany
- 700 1_
- $a Strunk, Johannes $u Division of Rheumatology, Porz am Rhein Hospital, Cologne, Germany
- 700 1_
- $a Cañete, Juan D $u Servicio de Reumatología, Hospital Clínic de Barcelona, Barcelona, Spain
- 700 1_
- $a Senolt, Ladislav $u Institute of Rheumatology, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Filkova, Maria $u Institute of Rheumatology, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Naredo, Esperanza $u Department of Rheumatology and Bone and Joint Research Unit, Hospital Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain
- 700 1_
- $a Largo, Raquel $u Department of Rheumatology and Bone and Joint Research Unit, Hospital Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain
- 700 1_
- $a Krönke, Gerhard $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a D'Agostino, Maria-Antonietta $u Unitá Operativa Complessa of Rheumatology, Agostino Gemelli University Polyclinic Foundation IRCCS, Catholic University of Sacred Heart, Rome, Italy
- 700 1_
- $a Østergaard, Mikkel $u University Hospital Rigshospitalet, Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Copenhagen, Glostrup, Denmark
- 700 1_
- $a Schett, Georg $u Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. Electronic address: georg.schett@uk-erlangen.de
- 773 0_
- $w MED00010161 $t Lancet $x 1474-547X $g Roč. 403, č. 10429 (2024), s. 850-859
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38364841 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155513 $b ABA008
- 999 __
- $a ok $b bmc $g 2081034 $s 1216581
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 403 $c 10429 $d 850-859 $e 20240213 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20240412
